599 related articles for article (PubMed ID: 30249526)
1. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
Hua W; Zhao Y; Jin X; Yu D; He J; Xie D; Duan P
Gynecol Oncol; 2018 Nov; 151(2):356-365. PubMed ID: 30249526
[TBL] [Abstract][Full Text] [Related]
2. Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression.
Lee DG; Lee SH; Kim JS; Park J; Cho YL; Kim KS; Jo DY; Song IC; Kim N; Yun HJ; Park YJ; Lee SJ; Lee HG; Bae KH; Lee SC; Shim S; Kim YM; Kwon YG; Kim JM; Lee HJ; Min JK
J Hepatol; 2015 Dec; 63(6):1429-39. PubMed ID: 26292259
[TBL] [Abstract][Full Text] [Related]
3. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
Bi X; Lv X; Liu D; Guo H; Yao G; Wang L; Liang X; Yang Y
Cancer Gene Ther; 2021 Apr; 28(3-4):335-349. PubMed ID: 32939058
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of methyltransferase like 3 in epithelial-mesenchymal transition process, invasion, and metastasis in esophageal cancer.
Liang X; Zhang Z; Wang L; Zhang S; Ren L; Li S; Xu J; Lv S
Bioengineered; 2021 Dec; 12(2):10023-10036. PubMed ID: 34666602
[TBL] [Abstract][Full Text] [Related]
5. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
6. TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.
Liu L; Wu N; Wang Y; Zhang X; Xia B; Tang J; Cai J; Zhao Z; Liao Q; Wang J
J Exp Clin Cancer Res; 2019 Feb; 38(1):106. PubMed ID: 30819230
[TBL] [Abstract][Full Text] [Related]
7. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract][Full Text] [Related]
8. Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells.
Liu ZF; Yang J; Wei SP; Luo XG; Jiang QS; Chen T; Gong YQ
Kaohsiung J Med Sci; 2020 Nov; 36(11):895-903. PubMed ID: 32668092
[TBL] [Abstract][Full Text] [Related]
9. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.
Koorstra JB; Karikari CA; Feldmann G; Bisht S; Rojas PL; Offerhaus GJ; Alvarez H; Maitra A
Cancer Biol Ther; 2009 Apr; 8(7):618-26. PubMed ID: 19252414
[TBL] [Abstract][Full Text] [Related]
10. AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
Rankin EB; Fuh KC; Taylor TE; Krieg AJ; Musser M; Yuan J; Wei K; Kuo CJ; Longacre TA; Giaccia AJ
Cancer Res; 2010 Oct; 70(19):7570-9. PubMed ID: 20858715
[TBL] [Abstract][Full Text] [Related]
11. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.
Vuoriluoto K; Haugen H; Kiviluoto S; Mpindi JP; Nevo J; Gjerdrum C; Tiron C; Lorens JB; Ivaska J
Oncogene; 2011 Mar; 30(12):1436-48. PubMed ID: 21057535
[TBL] [Abstract][Full Text] [Related]
12. Axl is a prognostic marker in oral squamous cell carcinoma.
Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265
[TBL] [Abstract][Full Text] [Related]
13. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA H19 regulates HIF-1α/AXL signaling through inhibiting miR-20b-5p in endometrial cancer.
Zhu H; Jin YM; Lyu XM; Fan LM; Wu F
Cell Cycle; 2019 Oct; 18(19):2454-2464. PubMed ID: 31411527
[TBL] [Abstract][Full Text] [Related]
15. Skipping of exon 10 in
Shen L; Lei S; Zhang B; Li S; Huang L; Czachor A; Breitzig M; Gao Y; Huang M; Mo X; Zheng Q; Sun H; Wang F
Theranostics; 2020; 10(13):5719-5735. PubMed ID: 32483414
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
17. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
Zhou L; Yang C; Zhang N; Zhang X; Zhao T; Yu J
Biomed Pharmacother; 2020 May; 125():109964. PubMed ID: 32044716
[TBL] [Abstract][Full Text] [Related]
18. HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis.
Song C; Zhou C
J Exp Clin Cancer Res; 2021 Feb; 40(1):62. PubMed ID: 33563300
[TBL] [Abstract][Full Text] [Related]
19. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A
Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564
[TBL] [Abstract][Full Text] [Related]
20. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL.
Abboud-Jarrous G; Priya S; Maimon A; Fischman S; Cohen-Elisha M; Czerninski R; Burstyn-Cohen T
Oncotarget; 2017 Feb; 8(8):13986-14002. PubMed ID: 28118606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
